Aspira Women's Health Inc. announced a material transfer agreement with The University of Oxford for the procurement of serum samples to be used to verify and validate the Company's endometriosis blood test algorithms. Aspira expects to use the samples to support the launch of EndoCheckSM, its first-generation blood test to aid in the diagnosis of endometriosis, by the end of 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.327 USD | +1.42% | -4.68% | -18.47% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.47% | 41.06M | |
-20.45% | 10.82B | |
+43.17% | 3.25B | |
-35.86% | 2.11B | |
-17.21% | 2.08B | |
-29.81% | 1.48B | |
+17.56% | 1.02B | |
-4.37% | 733M | |
-37.00% | 391M | |
-46.94% | 383M |
- Stock Market
- Equities
- AWH Stock
- News Aspira Women's Health Inc.
- Aspira Women's Health Inc. Signs Exclusive Sample Procurement Agreement with the University of Oxford